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The PCO may lead to either partial or complete obstruction 
of the visual axis thus causing the problems of decreased 
vision, increased glare and interference in the day to day 
activities of the patient. So to restore back proper vision 
lost due to PCO, removal of PCO is the only remedy.
Of the various interventions available for treatment of 
PCO, Nd: YAG laser capsulotomy is an established and 
safe procedure[3] for which photodisruption property 
of Nd: YAG laser (1064 nm) using Q-switched mode is 
utilized
Nd: YAG laser clears the visual axis by creating a 
central opening in the opacifi ed posterior capsule, but 
this procedure is not devoid of complications.
Transient rise of intraocular pressure (IOP) is the most 
common complication following laser capsulotomy, 
INTRODUCTION
Cataract surgery is currently the most common 
ophthalmic surgical procedure in the world. This 
procedure involves the extracapsular extraction of the 
opaque lens fi bers and implantation of an intraocular 
lens (IOL) which restores good vision.[1] However, 
posterior capsular opacifi cation (PCO), which is also 
termed as secondary cataract, is a common long-term 
complication of modern cataract surgery.[2]
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ABSTRACT
Purpose: To evaluate the role of prophylactic use of Timolol maleate (0.5%) eye drop in preventing rise of intraocular 
pressure (IOP) post Nd: YAG capsulotomy. Materials and Methods: A randomized, single-blinded, parallel group study 
conducted in 220 eyes, over a period of 18 months. Precapsulotomy baseline IOP, Slitlamp examination and grading of 
PCO was done. After instilling the test medication Nd: YAG laser capsulotomy performed. Post capsulotomy patients were 
assessed immediately, after 1 hour and 3 hours for IOP. Result: Precapsulotomy, mean IOP in Group I (use of placebo) 
was 15.30 ± 2.83 mm Hg as compared to 16.15 ± 2.48 mmHg in Group II (use of Timolol eyedrop), Group II mean IOP was 
signifi cantly higher (P = 0.019). However, immediately after the procedure mean IOP in Group I was 14.55 ± 2.87 mmHg as 
compared to 13.16 ± 3.72 mmHg in Group II thus showing mean IOP in Group II to be signifi cantly lower (P = 0.002). One hour 
and 3 hours after the procedure too, mean IOP in Group II was signifi cantly lower as compared to that in Group I (P < 0.001). 
With increasing grade of PCO reduction in post-procedure IOP was lower and reduction in IOP was maximum in patients 
requiring <30 milliJoules of total energy. Conclusion: A judicious control over energy use and post laser IOP monitoring can 
infl uence the trend of IOP rise in a positive manner. Whenever anticipated that >60 mJ of laser energy is required as in higher 
grades and younger age, prophylactically Timolol maleate 0.5% eye drop should be instilled before Nd: YAG capsulotomy 
while all other patients in which Timolol is not used, should be kept under observation after laser capsulotomy.
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create a 2-3 mm diameter opening in the center of the 
opacifi ed capsule with a minimum number of laser shots. 
Post capsulotomy, patients were assessed immediately, 
after 1 hour and 3 hours (hrs) respectively for IOP.
Statistical analysis
The data was analyzed using Statistical Package for 
Social Sciences. Independent samples “t”-test and 
analysis of variance has been used to compare the 
data. Chi-square test has been used to compare the 
proportions. The confi dence level of the study was kept 
at 95%, hence a “P” value less than 0.05 is indicated as a 
statistically signifi cant intergroup diff erence.
RESULTS
Age of patients ranged from 13 to 100 years with 
a mean age 57.86 ± 14.88 years in Group I and 
60.70 ± 11.24 years in Group II. Majority of subjects in 
both the groups were females and had PCO grades I 
and II. Mean post-surgery time lag for PCO formation 
was 3.16 ± 2.14 years in Group I and 3.51 ± 3.31 years in 
Group II. The two groups were matched statistically for 
age, gender, PCO grade and mean post-surgery time 
lag for PCO formation [Table 1].
Before the procedure, mean IOP in Group I was 
15.30 ± 2.83 mmHg as compared to 16.15 ± 2.48 mmHg 
in Group II, thus showing mean IOP in Group II to be 
signifi cantly higher (P = 0.019). However, immediately 
after the procedure the mean IOP in Group I was 
14.55 ± 2.87 mmHg as compared to 13.16 ± 3.72 mmHg 
in Group II thus showing mean IOP in Group II to 
be signifi cantly lower (P = 0.002). One hour and 3 hrs 
after the procedure too, mean IOP in Group II was 
signifi cantly lower as compared to that in Group I 
(P < 0.001) [Table 2].
On evaluating the impact of diff erent demographic, 
clinical and procedural variables on IOP change, 
impact of intervention (0.5% Timolol maleate), time 
which peaks in the fi rst 3 hrs of laser application.[4] The 
increase in IOP noted in previous literature is 5-10 mmHg 
which may lead to serious eye damage, especially in 
patients with advanced glaucoma who have higher 
frequency of this complication.[5]
For preventing the transient rise of IOP there are varied 
opinions about the use of Timolol maleate eye drops, 
which is a non-selective ß1 and ß2 adrenergic receptor 
antagonist and has an IOP lowering action by reducing 
aqueous humor production.[6]
Because of the lack of common consensus about the 
effi  cacy and need of pre-capsulotomy use of Timolol 
maleate in controlling diff erent ranges of raised IOP 
spikes, this study was undertaken with the aim to 
evaluate the role and effi  cacy of prophylactic use of 
Timolol maleate (0.5%) eyedrop in preventing rise of 
IOP post Nd: YAG capsulotomy.
MATERIALS AND METHODS
This was a randomized parallel group study conducted 
over a period of 18 months from November 2010 to July 
2012 at Era’s Lucknow medical college and hospital, 
Lucknow. The study was conducted in 220 eyes 
which were divided into two Groups (Gp.) with 110 eyes 
in each group after randomization. Gp. I included 
eyes in which placebo (artifi cial tear substitute) was 
instilled before the laser treatment whereas Gp. II 
included eyes in which Timolol maleate (0.5%) was 
instilled before the laser treatment. Patients excluded 
were those already using antiglaucoma medications, 
having absolute or relative contraindications to YAG 
capsulotomy (e.g. corneal edema, corneal ulcer, corneal 
scarring, presence of glass IOL, anterior uveitis, macular 
edema) and in those where use of Timolol maleate eye 
drop was contraindicated (e.g. Asthmatic and cardiac 
patients). Precapsulotomy assessment of patients 
was done for vision, baseline IOP (by Applanation 
tonometery), slit-lamp examination for any 
contraindication for the procedure as well as to grade the 
PCO (using Madurai Intraocular lens study IV[7,20]) 110 
eyes in group I were given placebo before capsulotomy 
while in the rest of 110 eyes comprising group II, 0.5% 
Timolol maleate eyedrop was instilled pre-casulotomy. 
Following instillation of eyedrops (Placebo/Timolol) 
patients were instructed to press over the puncta for 
5 minutes and keep the eyes closed. Topical anesthetic 
4% Paracaine was instilled and then a wide fi eld spectral 
Nd.YAG laser contact lens (Abraham’s contact lens) was 
placed over the cornea with viscoelastic substance as 
coupling agent. The slit-lamp beam was narrowed and 
obliquely angled (to help reduce miosis). Laser shots 
with low energy (1 milliJoule) were given initially and 
gradually increased as per requirement. Aim was to 














Male:Female 39:71 50:60 0.131
PCO grade
I and II 81 (73.6%) 69 (62.7%) 0.082
III and IV 29 (26.4%) 41 (37.3%)
Mean post surgery time 
lag for PCO formation±SD
3.16±2.14 3.51±3.31 0.354
PCO: Posterior capsular opacification, SD: Standard deviation, P<0.05 
(significant)
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lag since cataract surgery, grade of PCO and amount 
of total energy required were found to be signifi cantly 
associated with the change in IOP.
Immediately after the procedure, mean reduction in 
IOP was 0.75 ± 1.92 mmHg in Group I as compared to 
2.98 ± 2.91 in Group II (P < 0.001). At 1 hr after procedure, 
mean reduction in IOP was 0.11 ± 2.15 mmHg in 
Group I as compared to 2.69 ± 3.11 mmHg in Group II 
(P < 0.001). At 3 hrs after procedure interval, mean 
reduction in IOP was 1.90 ± 2.73 mmHg in Group II 
as compared to a mean increase in IOP to the tune of 
0.31 ± 1.97 mmHg in Group I (P < 0.001) [Table 3].
With increasing grade of PCO reduction in 
post-procedure IOP was lower and reduction in IOP 
was maximum in patients requiring <30 mJ of total 
energy [Table 4].
DISCUSSION
Nd: YAG laser posterior capsulotomy is the treatment 
of choice for the PCO. This procedure has gained 
popularity as it is non-invasive, relatively safer, less 
time consuming and free from infections as compared 
to needle capsulotomy but has been associated with 
complications like corneal burns, intra ocular lens pi  ing 
and raised IOP varying from 1.6%[8] to 42.85%.[9] In 
the present study, the focus was kept on IOP changes 
following Nd: YAG laser capsulotomy with and 
without pre-capsulotomy use of Timolol maleate 0.5% 
eye drops. It has been shown in literature that Timolol 
maleate 0.5% is a useful intervention to inhibit 
IOP rise following Nd: YAG laser posterior 
capsulotomy.[8,10,11] In our study no rise in mean IOP 
was observed in either Gp. I or Gp. II, instead a nominal 
reduction in mean IOP was observed in both groups I 
and II (0.75 ± 1.92 and 2.98 ± 2.91 mmHg, respectively). 
This diff erence was statistically signifi cant. At 3 hrs 
post-procedure interval, there was a rise in mean IOP 
in the placebo group (0.31 ± 1.97 mm Hg) whereas 
mean IOP in the Timolol maleate group was still lower 
by 1.90 ± 2.73 mm Hg as compared to precapsulotomy 
IOP which again was signifi cant statistically. Contrary 
to our study, Cai et al. (2008)[12] observed a mean rise 
of 0.9 mmHg in the treatment group as compared 
to 2.1 mmHg in the placebo group and in another 
previous study by Rakofsky et al. (1997),[10] 7% of the 
Timolol group and 36% of the placebo group an IOP 
Table 2: Comparison of change in IOP immediately 
after laser capsulotomy, at 1 hr, and at 3 hrs among 






Before procedure 15.30±2.83 16.15±2.48 0.019
Immediately after procedure 14.55±2.87 13.16±3.72 0.002
1 hr after procedure 15.41±2.63 13.45±3.92 <0.001
3 hrs after procedure 15.61±2.62 14.25±3.59 <0.001
IOP: Intraocular pressure, hr: Hour, P<0.05 (significant)
Table 3: Postcapsulotomy change in mean IOP 
as compared to baseline IOP in the two study 
groups, at different time intervals (values are 
mean±SD mmHg)





Immediately after procedure −0.75±1.92 −2.98±2.91 <0.001
1 hr after procedure −0.11±2.15 −2.69±3.11 <0.001
3 hrs after procedure 0.31±1.97 −1.90±2.73 <0.001
IOP: Intraocular pressure, Hr: Hour, SD: standard deviation, P<0.05 
(significant)
Table 4: Impact of different demographic and clinical 
variables on immediate change in intraocular 
pressure after Nd: YAG laser capsulotomy







Control 110 −0.75 1.92 <0.001
Test 110 −2.98 2.91
Age of patient
<50 34 −0.91 2.08 0.079
50-70 163 −2.06 2.85
>70 23 −1.91 2.15
Sex
Male 89 −1.51 2.82 0.105
Female 131 −2.11 2.59
Duration (years)
<1 3 0.00 0.00 0.017
1-5 180 −1.94 2.69
6-10 31 −1.06 2.19
>10 6 −4.50 3.99
Grade
I 73 −2.21 2.97 <0.001
II 77 −2.45 2.69
III 34 −1.50 1.86
IV 36 −0.25 2.16
Total energy required (mJ)
<30 86 −2.91 2.96 <0.001
30-60 59 −1.56 2.04
60-90 50 −0.76 2.43
>90 25 −1.20 2.50
Preoperative BCVA (LogMAR)
0 6 −1.17 2.79 0.284
0.1-0.3 60 −2.25 3.04
0.4-0.6 54 −2.22 2.74
0.7-0.9 40 −1.70 2.00
1 60 −1.33 2.67
IOP: Intraocular pressure, SD: Standard deviation, BCVA: Best corrected 
visual acuity, mJ: Millijoules, Nd: YAG laser: Neodymium doped yttrium 
aluminum garnet laser, LogMAR: logarithm of minimum angle of resolution, 
P<0.05 (significant)
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rise of >5 mm Hg was observed. However, in our study, 
no such increase in IOP was observed in Group II 
(Timolol) while in Group I (placebo) also minimal rise 
of IOP was observed and that too only at 3 hour interval 
post laser capsulotomy. The reason for such nominal 
increase in IOP could be explained by the delivery of 
shorter energy packets per shot and lower total energy 
used in our study. In the present study, 86 (39.1%) eyes 
received total energy <30 mJ whereas only 75 (34.1%) 
eyes received total energy >60 mJ. The impact of amount 
of energy used on IOP rise has been shown by Waseem 
and Khan et al. (2010)[13] and in our study also there 
was a signifi cant association between the total amount 
of energy used and change in IOP [Table 4]. In Gp. II, 
irrespective of total amount of energy delivered, at no 
post Nd: YAG capsulotomy stage there occurred any 
rise of IOP. While in Gp. I, there occurred an elevation 
of IOP only in those cases in which total laser energy 
was >60 mJ and it was also statistically not signifi cant. 
But when laser energy was <30 mJ, instead of rise, 
a fall in IOP was observed immediately after YAG 
capsulotomy (P < 0.001). This was in concurrence with 
the study by Khanzada et al. (2008)[14] where low energy 
levels used for laser capsulotomy lead to, IOP rise in only 
3.1% cases in their study. It was explained by use of less 
total energy delivered leading to minimal production 
of prostaglandins, thereby not leading to post laser rise 
in IOP. Apart from the laser intervention, we found that 
duration between cataract surgery and PCO formation 
as well as grade of PCO has a signifi cant association 
with the amount of IOP rise. Similar associations have 
also been shown by Shaikh et al. (2010).[15]
Thus, the fi ndings of the present study help us to 
conclude that judicious control over laser energy 
delivery can infl uence the trend of IOP rise. Whenever 
anticipated that >60 mJ of energy is required as in higher 
grades of PCO and younger age, prophylactically 
Timolol maleate 0.5% eye drop should be instilled 
before Nd: YAG capsulotomy while all the other 
patients should just be kept under observation.
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SUMMARY STATEMENT
A randomized, single-blinded, parallel group 
study conducted on 220 eyes, to evaluate the role of 
prophylactic use of Timolol maleate (0.5%) eyedrop 
in preventing rise of IOP post Nd: YAG capsulotomy. 
Precapsulotomy baseline IOP, Slit lamp examination 
and grading of PCO was done. After instilling the test 
medication Nd: YAG laser capsulotomy was performed. 
We found that with precapsulotomy use of Timolol, 
irrespective of total amount of energy delivered, at no 
post Nd: YAG capsulotomy stage there occurred any rise 
of IOP. While in other cases with precapsulotomy use 
of placebo, with energy amount >60 mJ there occurred 
an elevation of IOP (statistically not signifi cant). Thus, 
prophylactically precapsulotomy Timolol maleate 0.5% 
eye drop should be instilled in higher grades, younger 
age and if >60 mJ total energy is required.
REFERENCES
1. Beebe DC. The lens. In: Kaufman PL, Alm A, editors. Adler’s 
Physiology of the Eye: Clinical Application. 10th ed. St Louis, MO: 
Mosby–Year Book; 2003. p. 117-58.
2. Spalton DJ. Posterior capsular opacifi cation after cataract surgery. 
Eye 1999;13:489-92.
3. Stark WJ, Worthen D, Holladay JT, Murray G. Neodymium: YAG 
Lasers: An FDA Report. Ophthalmology 1985;92:209-12.
4. Bhattacharyya B. Nd: YAG Posterior Capsultomy. Clinical Applications: 
YAG Laser (Ophthalmology). 1st ed. Jaypee; New Delhi, India; 2005. 
p. 28-54.
5. Ge J, Wand M, Chiang R, Paranhos A, Shields MB. Long-term effect 
of Nd: YAG laser posterior capsulotomy on intraocular pressure. Arch 
Ophthalmol 2000;118:1334-7.
6. Allingham RR, Damji KG, Freedman SF, Moroi SE, Rhee DJ, 
Shields MB. Adrenergic Recptor Antagonists. Shield’s Textbook of 
Glaucoma. 6th ed. Lippincott Williams and Wilkins; Philadelphia, USA; 
2005. p. 457.
7. Aslam TM, Patton N. Methods of assessment of patients for Nd: YAG 
Laser capsulotomy that correlate with fi nal visual improvement. BMC 
ophthalmol 2004;4:13.
8. Hussain MM. Complications after Nd: YAG Laser Capsulotomy. Pak 
J Ophthalmol 1996;12:13-5.
9. Alimanovic-Halilovic E. [Complications in the posterior eye segment 
after Nd: YAG laser capsulotomy]. Med Arh 2004;58: 7-9.
10. Rakofsky S, Koch DD, Faulkner JD, Terry SA, Mandell AI, Gross RL, 
et al. Levobunolol 0.5% and timolol maleate 0.5% to prevent 
intraocular pressure elevations after Nd-YAG laser posterior 
capsulotomy. J Cataract Refract Surg 1997;23:1075-80.
11. Allingham RR, Damji KG, Freedman SF, Moroi SE, Rhee DJ, 
Shields MB. Adrenergic Recptor Antagonists. In: Shield’s Textbook 
of Glaucoma. 6th ed. Lippincott Williams and Wilkins; Philadelphia, 
USA; 2011. p. 542-7.
12. Cai JP, Cheng JW, Wei RL, Ma XY, Jiang F, Zhu H, et al. Prophylactic 
use of timolol maleate to prevent intraocular pressure elevation after 
Nd-YAG laser posterior capsulotomy. Int Opthalmol 2008;28:19-22.
13. Waseem M, Khan HA. Association of raised intraocular pressure 
and its correlation to the energy used with raised versus normal 
intraocular pressure following Nd: YAG laser posterior capsulotomy 
in pseudophakes. J Coll Physicians Surg Pak 2010;20:524-7.
14. Khanzada MA, Jatoi SM, Narsani AK, Dabir SA, Gul S. Is the Nd: YAG 
Laser a safe procedure for posterior capsulotomy. Pak J Ophthalmol 
2008;24:73-8.
15. Shaikh A, Shaikh F, Adwani JR, Shaikh ZA. Prevalence of different 
Nd: YAG Laser induced complication in patients with signifi cant 
posterior capsule opacifi cation and their correlation with time duration 
after standard cataract surgery. Int J Med Med Sci 2010;2:12-7.
How to cite this article:***
Source of Support: Nil, Confl ict of Interest: None declared
